Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus

Authors

Bo-Wen Sun
Peng-Peng Zhang
Zong-Hao Wang
Xia Yao
Meng-Lan He
Rui-Ting Bai
Hao Che
Jing Lin
Tian Xie
Zi Hui
Xiang-Yang Ye
Li-Wei Wang

Publication Date

1-25-2024

Journal

Molecules

Abstract

Respiratory syncytial virus (RSV) is a significant viral pathogen that causes respiratory infections in infants, the elderly, and immunocompromised individuals. RSV-related illnesses impose a substantial economic burden worldwide annually. The molecular structure, function, and in vivo interaction mechanisms of RSV have received more comprehensive attention in recent times, and significant progress has been made in developing inhibitors targeting various stages of the RSV replication cycle. These include fusion inhibitors, RSV polymerase inhibitors, and nucleoprotein inhibitors, as well as FDA-approved RSV prophylactic drugs palivizumab and nirsevimab. The research community is hopeful that these developments might provide easier access to knowledge and might spark new ideas for research programs.

Keywords

respiratory syncytial virus (RSV), monoclonal antibodies, vaccine, molecule inhibitor

Comments

PMID: 38338343